Showing results (1111-1120 of 4,514) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|July 27, 2023
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myelomaThomas G Martin, Deepu Madduri, Lida Pacaud, et al.
Future Oncology (London, England)|August 1, 2023
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancerHampig Raphael Kourie, Mervat Mahrous, Nabih Naim, et al.
Future Oncology (London, England)|July 27, 2023
Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community settingDavid Waterhouse, Candice Yong, Andrew Frankart, et al.
Future Oncology (London, England)|July 14, 2023
Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse eventsSaadettin Kilickap, Sertac Ak, Oldac U Dursun, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Future Oncology (London, England)|June 15, 2023
Uncovering cancer's secrets: could liquid biopsies and artificial intelligence hold the answers?Jade Parker
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Future Oncology (London, England)|June 9, 2023
Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysisLinlin Yang, Butuo Li, Yiyue Xu, et al.
Future Oncology (London, England)|July 27, 2026
Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world studyYanhui Zhang, Yuqin Jin, Ruidan Zhang, et al.
Future Oncology (London, England)|July 20, 2026
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumorsHans Gelderblom, Emanuela Palmerini, Michiel van de Sande, et al.
Pageof 452